Urokinase in rheumatoid arthritis: Causal or coincidental?

Annals of the Rheumatic Diseases

Volumn 56, Issue 12, 1997, Pages 705-706

  Busso, Nathalie ^a   So, Alexander ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

STANOZOLOL; UROKINASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CORTICOSTEROID THERAPY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM;

EID: 0031406601     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.12.705     Document Type: Article

References (32)

1. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
2. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
3. Ronday HK, Smits HH, van Muijen GN, Pruszcynski MS, Dolhain RJ, van Langelaan EJ, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996;35:416-23.
4. Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997;56:550-7.
5. Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991;34:996-1005.
6. Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost 1992;68:180-4.
7. Kummer JA, Abbink JJ, de Boer JP, Roem D, Nieuwenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-93.
8. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-6.
9. Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluid from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis 1996;55:230-6.
10. Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 1992;51:965-8.
11. Hamilton JA, Campbell IK, Wojta J, Cheung D. Plasminogen activators and their inhibitors in arthritic disease. Ann NY Acad Sci 1992;667:87-100.
12. Allan EH, Martin TJ. The plasminogen activator inhibitor system in bone cell function. Clin Orthop 1995;313:54-65.
13. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase activity. FEBS Lett 1992;267:14151-6.
14. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994;269:14746-50.
15. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 4th ed. Philadelphia: W B Saunders, 1993:248-68.
16. Collier S, Ghosh P. The role of plasminogen in interleukin-1 mediated cartilage degradation. J Rheumatol 1988;15:1129-37.
17. Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 1990;33:542-52.
18. Ronday HK, Smits HH, Quax PHA, Van Der Pluijm G, Lowik CWGM, Breedveld FC, et al. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997;36:9-15.
19. Zacharski LR, Brown FE, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol 1992;63:155-62.
20. Harris ED. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 4th ed. Philidelphia: W B Saunders, 1993:833-873
21. Collen D, Lijnen HR. Fibrin-specific fibrinolysis. Ann N Y Acad Sci 1992; 667:259-71.
22. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996;97:2440-51.
23. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995;96:1621-30.
24. Dvorak HN, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985;227:1059-61.
25. Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986;77:1014-9.
26. Altieri DC. Coagulation assembly on leukocytes in transmembrane signaling and cell adhesion. Blood 1993;81:569-79.
27. Dumonde DC, Glynn LE. The production of arthritis in rabbits by an immunological reaction to fibrin. Br J Exp Pathol 1962;43:373-83.
28. Gordon M, Bullough PG. Synovial and osseous inflammation in failed silicone-rubber prostheses. J Bone Joint Surg 1982;64:574-80.
29. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomatenals. J Exp Med 1993;178:2147-56.
30. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987;14:439-45.
31. Belch JJ, Madhok R, McArdle B, McLaughlin K, Kluft C, Forbes CD, et al. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Q J Med 1986;58:19-27.
32. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24.